Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Hayes

Nurse Practitioner, Psychiatric/Mental Health Mobile, AL Nurse Practitioner

NPI 1023285228 CMS profile 11069934

2400 Gordon Smith Dr, Mobile, AL 36617

Open in the dashboard

General payments

$29,636

232 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Hayes of Mobile, AL is reported in the CMS Open Payments database as having received $29,636 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2024 General $196 10
2023 General $8,251 41
2022 General $19,742 94
2021 General $1,431 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Hayes
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to John Hayes were reported at $15. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year John Hayes Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,431 $166 $54–$482 $132
2022 $19,742 $195 $66–$559 $149
2023 $8,251 $233 $82–$673 $160
2024 $196 $236 $84–$688 $164
2025 $15 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $26,801 58 payments
  2. ITI, Inc. $833 46 payments
  3. Otsuka America Pharmaceutical, Inc. $766 50 payments
  4. Neurocrine Biosciences, Inc. $320 17 payments
  5. Janssen Pharmaceuticals, Inc $315 21 payments
  6. AbbVie, Inc. $238 20 payments
  7. Teva Pharmaceuticals USA, Inc. $82 4 payments
  8. Vanda Pharmaceuticals Inc. $56 4 payments
  9. Indivior Inc. $56 3 payments
  10. Ironshore Pharmaceuticals Inc. $49 2 payments
  11. Other $121 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,550 11 payments
  2. Food and Beverage $4,773 204 payments
  3. Travel and Lodging $3,212 14 payments
  4. Consulting Fee $3,050 1 payment
  5. Education $50 2 payments
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $20,038 42 payments
  2. LYBALVI Cns $14,528 37 payments
  3. LYBALVI Cns $14,352 28 payments
  4. LYBALVI Cns $14,352 28 payments
  5. ARISTADA Cns $12,448 30 payments
  6. ARISTADA Cns $12,448 30 payments
  7. ARISTADA Cns $12,273 21 payments
  8. ARISTADA Cns $12,273 21 payments
  9. ARISTADA INITIO $6,938 25 payments
  10. CAPLYTA $833 46 payments
  11. Other $3,000 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,225

Median for Nurse Practitioner: 389

Drug cost

$542,863

Median for Nurse Practitioner: $21,885

Branded share of claims

26.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 29 $229,484
Invega Sustenna Paliperidone Palmitate Brand 39 $95,917
Abilify Maintena Aripiprazole Brand 26 $71,716
Aristada Aripiprazole Lauroxil Brand 11 $35,350
Vraylar Cariprazine Hcl Brand 21 $29,363
Risperdal Consta Risperidone Microspheres Brand 13 $24,012
Trintellix Vortioxetine Hydrobromide Brand 42 $20,175
Lurasidone Hcl Generic 39 $6,642
Aripiprazole Generic 36 $5,100
Asenapine Maleate Generic 13 $3,960

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$908

Medicare's payments for the services billed

Medicare patients

33

Average age 53

Services billed

37

16 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 52%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $54
$54 21 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $41
$41 — —
PERSERIS
  • Indivior Inc. $25
$25 — —
CAPLYTA
  • ITI, Inc. $21
$21 — —
Azstarys
  • Corium, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record